1. Scrip
  2. >>Business
  3. >>Strategy

Cardiovascular Drugs

 
• By Jeff Dvorin

The three start-ups profiled in this group of companies are employing a variety of scientific platforms and business models to develop treatments for cardiovascular disease. Excigen (gene therapy to treat arrhythmias) and Endogeny (cell therapy to repair damaged heart tissue) are using cutting-edge approaches to discover and develop novel therapeutics, while QuatRx is an in-licensing company with a lipid -regulating compound that may enter the clinic next year. What all three have in common is a focus on products and an intent to outlicense their products for late-stage development and commercialization.

Cardiovascular disease (CVD) exacts a staggering human and economic toll each year. It claims more American lives than the next five leading causes of death combined and, with the exception of the influenza-ridden year of 1918, has been the number one killer in the US since 1900. Nearly 40% of all deaths in the US result from CVD. And with an aging baby boom population (over a third of all Americans between the ages of 45 and 54 have CVD), an increasingly sedentary lifestyle, and growing rates of obesity, those numbers are unlikely to go down any time soon.

It's a health problem so prevalent that two University of London scientists recently announced that they are working on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.